Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Fennec Pharmaceuticals Q3 EPS $(0.07) Beats $(0.11) Estimate, Sales $6.51M Beat $5.42M Estimate

Author: Benzinga Newsdesk | November 06, 2023 07:05am
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by 36.36 percent. This is a 77.42 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $6.51 million which beat the analyst consensus estimate of $5.42 million by 20.20 percent.

Posted In: FENC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist